CME Supplement

Ospemifene, an oral SERM for dyspareunia of menopause: Is it being underutilized?

This activity is supported by an educational grant from Duchesnay

 

Estrogen and androgen deficiency from menopause causes vulvovaginal and urogenital changes and a plethora of symptoms, most prominently dyspareunia.

Read the supplement and earn CME credit for your knowledge of the following:

  • The pathophysiology of dyspareunia due to vulvovaginal atrophy (VVA) of menopause.
  • The underrecognition and undertreatment of dyspareunia due to VVA.
  • Efficacy results of randomized placebo controlled trials of ospemifene.
  • Adverse events associated with ospemifene.
  • Safety data of ospemifine as well as other oral selective estrogen receptor modulators and estrogens.

Click on the image above or here to read the supplement and earn credit